GE HealthCare and Medis Medical Imaging have announced a collaboration that they say is aimed at helping advance precision care in the diagnosis and treatment of coronary artery disease (CAD).
The two companies further the development and commercialisation of Medis Quantitative Flow Ratio (Medis QFR), a non-invasive approach to the assessment of coronary physiology, as part of GE HealthCare’s interventional cardiology portfolio built around the Allia Platform.
The collaboration seeks to provide access to emerging technologies, like Medis QFR, while also reducing complexity in the cath lab to improve the operating environment for clinicians, the companies said in a press release.
“We continue to see an evolution in how clinicians work to treat cardiovascular disease and want to give clinicians the tools, along with the flexibility and adaptability, they need to enable better outcomes for their patients,” says Arnaud Marie, general manager for global intervention at GE HealthCare. “In the assessment of coronary artery disease, QFR represents a significant advancement in how efficiently it can provide critical insights. We’re excited to collaborate with Medis Medical Imaging to add innovative, non-invasive, image-based QFR to our portfolio of offerings around our Allia IGS platform to streamline the experience for clinicians and help us to deliver on our vision for the future image-guided therapy.”
Medis’ QFR is a proprietary solution that delivers image-based physiology of coronary obstructions based on angiography imaging analysis alone. The technology can help clinicians select the ultimate lesion(s) for treatment and create the right treatment plan for a balloon or stent-based percutaneous coronary intervention (PCI) procedure, while also helping the clinician evaluate the efficacy of that treatment.
The analysis can be performed in real time while the patient is on the table and results are displayed on the large display monitor in the cath lab.
“We are absolutely delighted to be taking this next step with GE HealthCare, a fellow leader in the interventional cardiology domain,” says Maya Barley, CEO Medis Medical Imaging. “Building on Medis QFR’s decade of AI research, customer-focused product development, clinical evidence generation and business development, we are excited to be able to further accelerate our efforts around Medis QFR to enable more hospitals and clinicians to apply physiology in day-to-day interventional practice a part of best-practice clinical care – making this technology more accessible and available to patients than ever before.”
